Please use this identifier to cite or link to this item:
Title: New anticonvulsants.
Austin Authors: Vajda, F J
Affiliation: Department of Neurology, Austin Hospital, University of Melbourne, Heidelberg, Victoria, Australia
Issue Date: 1-Aug-1992
Publication information: Current Opinion in Neurology and Neurosurgery; 5(4): 519-25
Abstract: The development of antiepileptic drugs has been rather slow, and this may be related partly to the regulatory requirement to show unequivocal benefit of a new agent over existing drugs. There is a need to reconsider trial protocols to achieve this objective. Five new drugs, vigabatrin (GVG), lamotrigine (LTG), gabapentin (GPT), felbamate and oxcarbazepine (OCBZ) appear to be the most widely tested and promising agents. Of the others, loreclezole and stiripentol (STP) are showing the highest potential for therapeutic application. Clobazam appears to be more effective than implied from earlier reports.
Gov't Doc #: 1325225
Journal: Current opinion in neurology and neurosurgery
Type: Journal Article
Subjects: Animals
Anticonvulsants.therapeutic use
Brain.drug effects.physiopathology
Epilepsy.drug therapy.physiopathology
Receptors, GABA-A.drug effects.physiology
Synaptic Transmission.drug effects.physiology
gamma-Aminobutyric Acid.physiology
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on May 28, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.